Long arginine 3-IGF-1, abbreviated as IGF-1 LR3 or as LR3-IGF-1, is a synthetic protein and lengthened analogue of human insulin-like growth factor 1 (IGF-1). As a result, it is approximately three times more potent than IGF-1,[3] and possesses a significantly longer half-life of about 20–30 hours (relative to IGF-1’s half-life of about 12–15 hours).
IGF-1 LR3 has many benefits ranging from its cardio-protective ability to better lower brain cell regeneration and function. It will slow down muscle tissue degeneration and it will also assist with the synthesis of proteins.
This peptide has the ability to change your body so that it’s able to create better muscle density over the long term, particularly useful in patients with muscular dystrophy. This happens due to hyperplasia with the net result being, increased muscle mass.
Role of IGF-I signalling in muscle bone interactions.
Bikle DD1, Tahimic C1, Chang W1, Wang Y1, Philippou A2, Barton ER3.
Author information
Abstract
Skeletal muscle and bone rely on a number of growth factors to undergo development, modulate growth, and maintain physiological strength. A major player in these actions is insulin-like growth factor I (IGF-I). However, because this growth factor can directly enhance muscle mass and bone density, it alters the state of the musculoskeletal system indirectly through mechanical crosstalk between these two organ systems. Thus, there are clearly synergistic actions of IGF-I that extend beyond the direct activity through its receptor. This review will cover the production and signaling of IGF-I as it pertains to muscle and bone, the chemical and mechanical influences that arise from IGF-I activity, and the potential for therapeutic strategies based on IGF-I. This article is part of a Special Issue entitled “Muscle Bone Interactions”